KidCove: A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Children 6 months to < 12 Years of Age

Principal Investigator: Dr. Sergio Fanella

The study is divided into 3 parts. Parts 1 and 2 will be divided into 3 age groups ( 6 mos- 12yrs).
The purpose of Part 1 was to identify the optimal (safest and most effective) dose level for each age group.
The purpose of Part 2 is to study the optimal (safest and most effective) dose from Part 1 to see how well it works to prevent COVID-19.
The purpose of Part 3 is to study a lower dose of mRNA-1273 vaccine for the oldest age group.
ClinicalTrials.gov Identifier: NCT04796896